BMC Endocrine Disorders最新文献

筛选
英文 中文
Immunohistochemical evaluation of apelin and VEGF expression in cortisol-producing adrenal adenomas. 促肾上腺皮质激素腺瘤中apelin和VEGF表达的免疫组化评价。
IF 3.7 3区 医学
BMC Endocrine Disorders Pub Date : 2026-09-16 DOI: 10.1186/s12902-026-02563-w
Hatice Çalişkan Burgucu, Tuğba Günler, Ethem Ömeroğlu, Yaşar Ünlü, Oğuzhan Aksu
{"title":"Immunohistochemical evaluation of apelin and VEGF expression in cortisol-producing adrenal adenomas.","authors":"Hatice Çalişkan Burgucu, Tuğba Günler, Ethem Ömeroğlu, Yaşar Ünlü, Oğuzhan Aksu","doi":"10.1186/s12902-026-02563-w","DOIUrl":"10.1186/s12902-026-02563-w","url":null,"abstract":"<p><strong>Purpose: </strong>In this study, we aimed to investigate the immunohistochemical expression of apelin in tissue samples obtained from patients with Cushing's syndrome (CS) due to cortisol-producing adrenal adenoma (CPA) and to compare these findings with normal adrenal cortex tissue. Additionally, we sought to evaluate the association of apelin expression with clinical, hormonal, and histopathological parameters. The expression profile of vascular endothelial growth factor (VEGF) was also assessed to explore potential angiogenic interactions.</p><p><strong>Methods: </strong>This retrospective, single-center study included 11 patients diagnosed with CPA and 15 control subjects with histologically normal adrenal cortex tissue. Formalin-fixed, paraffin-embedded tissue sections were subjected to immunohistochemical staining for apelin and VEGF. Immunohistochemical evaluation was performed by assessing staining intensity and the percentage of positively stained cells. An immunoreactivity score (IRS) was calculated by combining these parameters to provide a semi-quantitative measure of protein expression.</p><p><strong>Results: </strong>Apelin staining intensity was significantly higher in CPA tissues compared with controls (p = 0.026), whereas the percentage of apelin-positive cells and IRS values did not differ significantly between groups. In an exploratory ROC analysis, apelin staining intensity showed moderate discrimination between CPA and control adrenal cortex tissues (AUC = 0.776, 95% CI: 0.581-0.971, p = 0.018). In bias-reduced univariable logistic regression, apelin staining intensity was associated with CPA (OR = 2.96, 95% CI: 1.02-8.60, p = 0.046), although the wide confidence interval indicated considerable uncertainty. VEGF staining parameters did not differ significantly between CPA and control tissues. No statistically significant correlations could be demonstrated between apelin or VEGF IRS and the evaluated clinicopathological or hormonal parameters.</p><p><strong>Conclusion: </strong>Apelin staining intensity was higher in CPA than in normal adrenal cortex, whereas the proportion of apelin-positive cells and IRS did not differ significantly between groups. VEGF staining parameters also did not differ significantly between CPA and control tissues. These findings suggest altered apelin immunoreactivity in CPA; however, given the exploratory nature and small sample size of the study, larger studies are required to confirm these observations and clarify their biological significance.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"26 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13579810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis. 在伴有或不伴有糖尿病的肥胖患者中,12mg或36mg维持剂量的疗效和安全性:一项系统评价和综合荟萃分析。
IF 3.7 3区 医学
BMC Endocrine Disorders Pub Date : 2026-09-15 DOI: 10.1186/s12902-026-02538-x
Mohamed Gamal Hegaz, Mohammad Yassin Al Aboud, Abanoub I I Kamel, Muhammad Abdullah Naveed, Omar Gamal Elsayed, Aqsa Zoey Sorathia
{"title":"Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.","authors":"Mohamed Gamal Hegaz, Mohammad Yassin Al Aboud, Abanoub I I Kamel, Muhammad Abdullah Naveed, Omar Gamal Elsayed, Aqsa Zoey Sorathia","doi":"10.1186/s12902-026-02538-x","DOIUrl":"10.1186/s12902-026-02538-x","url":null,"abstract":"<p><strong>Background: </strong>Obesity is projected to affect about one billion adults by 2030 and is associated with cardiometabolic morbidity. Orforglipron is an oral, non-peptide glucagon-like peptide-1 receptor agonist developed to provide weight and metabolic benefits. Prior meta-analyses have supported its efficacy and safety but were limited by shorter follow-up and a predominance of non-diabetic populations. This meta-analysis aims to provide the most comprehensive head-to-head comparison between the two most commonly studied maintenance doses (12 mg vs. 36 mg), assessing weight, glycemic, cardiometabolic, and safety outcomes.</p><p><strong>Methods: </strong>We searched PubMed, Web of Science, Cochrane, and Scopus until March 1, 2026, for randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults. Outcomes of interest included percentage and absolute body weight change, BMI, HbA1c, waist circumference, lipid parameters, blood pressure, and adverse events. Results were pooled using a fixed-effects model, and prespecified subgroup analyses examined differences by diabetes status and treatment duration.</p><p><strong>Results: </strong>Six RCTs (3459 participants) were included. Compared with the 12 mg dose, the 36 mg dose was associated with greater reductions in percentage body weight change (p < 0.00001), absolute body weight change (p < 0.00001), body mass index (p < 0.00001), HbA1c (p < 0.00001), waist circumference (P < 0.00001), percent change in triglycerides (P = 0.002), and systolic blood pressure (P = 0.002). Adverse events were comparable between doses. No significant differences were observed in gastrointestinal events or pancreatic functions. A small difference in pulse rate was noted but was not considered clinically significant.</p><p><strong>Conclusion: </strong>In obese adults, orforglipron 36 mg improved weight and metabolic outcomes compared with 12 mg. No statistically significant differences between doses were detected for the prespecified safety outcomes, although small increases in ALT and AST were observed with the 36 mg dose and the trials included were not powered to detect rare or long-term adverse events. These findings support consideration of the higher maintenance dose when clinically appropriate. Longer-term studies are needed to confirm the benefit and cardiovascular outcomes.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"26 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13579720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of SGLT-2 inhibitors on thyroid-stimulating hormone and systemic immune-inflammation index in type 2 diabetes: a retrospective study. SGLT-2抑制剂对2型糖尿病患者促甲状腺激素和全身免疫炎症指数影响的回顾性研究
IF 3.7 3区 医学
BMC Endocrine Disorders Pub Date : 2026-09-11 DOI: 10.1186/s12902-026-02483-9
Seyit Murat Bayram, Hüseyin Demirci, Enes Üçgül, Şule Canlar, Murat Cinel, Burak Menekşe, İlknur Alkan Kuşabbi, Erman Çakal
{"title":"Effects of SGLT-2 inhibitors on thyroid-stimulating hormone and systemic immune-inflammation index in type 2 diabetes: a retrospective study.","authors":"Seyit Murat Bayram, Hüseyin Demirci, Enes Üçgül, Şule Canlar, Murat Cinel, Burak Menekşe, İlknur Alkan Kuşabbi, Erman Çakal","doi":"10.1186/s12902-026-02483-9","DOIUrl":"10.1186/s12902-026-02483-9","url":null,"abstract":"<p><strong>Background/aim: </strong>This retrospective study examined whether long-term SGLT-2i use is associated with differences in thyroid-stimulating hormone (TSH) and the systemic immune-inflammation index (SII) in patients with type 2 diabetes mellitus (T2DM) without known thyroid disease. The neutrophil-to-lymphocyte ratio (NLR), renal function (eGFR), diabetes duration, and metformin use were also evaluated as potential covariates.</p><p><strong>Methods: </strong>This was a single-center, retrospective observational study. Adults with T2DM who had used empagliflozin or dapagliflozin for at least six months were compared with an age- and sex-matched control group of patients with T2DM not using SGLT-2i, drawn from the same outpatient clinics. Key exclusion criteria included known thyroid disease, known positivity for thyroid autoantibodies, active inflammatory or autoimmune processes, advanced organ failure, and immunomodulatory treatment. TSH, SII, and NLR were measured. Statistical analyses included intergroup comparisons, correlation, multivariate linear regression, post-hoc power calculation, and multicollinearity diagnostics (variance inflation factor, VIF).</p><p><strong>Results: </strong>The study included 330 patients across the empagliflozin (n = 139), dapagliflozin (n = 85), and control (n = 106) groups. Median TSH (1.6, 1.8, and 1.9 µIU/mL; p = 0.338) and SII (481, 531, and 468.5; p = 0.509) did not differ significantly between groups. SII and NLR were significantly correlated (r = 0.467, p < 0.001). In multivariate regression, female sex (B = 0.161, p = 0.015) and eGFR (B=-0.0043, p = 0.037) were independent predictors of log-transformed TSH; SGLT-2i use, SII, NLR, age, metformin use, and diabetes duration were not. The study had 80% power to detect a Cohen's f of 0.17 or greater; observed effect sizes were substantially below this threshold (f = 0.02 for TSH, f ≈ 0.00 for SII).</p><p><strong>Conclusion: </strong>Long-term SGLT-2i use was not associated with significant changes in TSH or SII in patients with T2DM without known thyroid disease, and the achieved effect sizes suggest that any true effect, if present, is likely small. Renal function emerged as an independent correlate of TSH, suggesting that the relationship between the hypothalamic-pituitary-thyroid axis and renal physiology merits further attention in this population, independent of SGLT-2i exposure. Prospective, multicenter studies incorporating free thyroxine and triiodothyronine measurements are warranted to further clarify these relationships.</p><p><strong>Clinical trial number: </strong>This study is retrospective and does not involve a clinical trial registration.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"26 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13670596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperinsulinemia and its associations with arterial stiffness and myocardial injury: a real-world cohort study. 高胰岛素血症及其与动脉僵硬和心肌损伤的关系:一项真实世界的队列研究。
IF 3.7 3区 医学
BMC Endocrine Disorders Pub Date : 2026-09-01 DOI: 10.1186/s12902-026-02521-6
Hongzhou Liu, Jing Liu, Nan Li, Yang Hua, Haixin Wang, Xian Deng, Linlin Wang, Song Dong, Xiaomin Fu, Shuangtong Yan
{"title":"Hyperinsulinemia and its associations with arterial stiffness and myocardial injury: a real-world cohort study.","authors":"Hongzhou Liu, Jing Liu, Nan Li, Yang Hua, Haixin Wang, Xian Deng, Linlin Wang, Song Dong, Xiaomin Fu, Shuangtong Yan","doi":"10.1186/s12902-026-02521-6","DOIUrl":"10.1186/s12902-026-02521-6","url":null,"abstract":"<p><strong>Background: </strong>Hyperinsulinemia is an early metabolic abnormality commonly associated with insulin resistance, but its relationship with cardiovascular injury in real-world populations remains incompletely understood. We examined whether fasting insulin is related to arterial stiffening and early myocardial biomarker abnormalities in a large health-examination population.</p><p><strong>Methods: </strong>This real-world retrospective analysis enrolled 30,343 adults who received routine health examinations from January 2017 to November 2021. For individuals with multiple visits, the earliest examination was used as the baseline record. Fasting insulin was evaluated in quartile categories, a log-transformed continuous exposure, and a hyperinsulinemia indicator based on the cohort-specific 75th percentile. The binary arterial-stiffness endpoint was defined using a mean baPWV (brachial-ankle pulse wave velocity) threshold of 1400 cm/s or higher. Myocardial injury was evaluated by cardiac troponin I or T. Logistic regression models were fitted to quantify the relationships of fasting insulin and HOMA-IR (homeostatic model assessment of insulin resistance) with baPWV-related outcomes and myocardial injury markers. Dose-response patterns were explored using restricted cubic spline modeling. Subgroup analysis and sensitivity analysis were performed. Python (3.13.0) was used for statistical analysis.</p><p><strong>Results: </strong>Higher insulin categories were accompanied by greater adiposity, blood pressure, glucose, HOMA-IR, triglycerides, baPWV, and arterial-stiffness. Hyperinsulinemia was correlated with arterial stiffness in the unadjusted model and adjusted model (OR, 1.31; 95% CI, 1.22-1.40, P < 0.001). Compared with the lowest insulin quartile, the highest quartile was associated with markedly increased odds of arterial stiffness (OR, 1.56; 95% CI, 1.41-1.74, P < 0.001). Spline curves indicated that fasting insulin and HOMA-IR were positively and non-linearly related to mean baPWV. In contrast, the association between hyperinsulinemia and composite myocardial injury was not statistically significant.</p><p><strong>Conclusions: </strong>In this large real-world health examination cohort, hyperinsulinemia was independently and consistently associated with increased arterial stiffness. However, its association with subclinical myocardial injury was weaker. These results support fasting insulin as a potential early metabolic indicator of vascular stiffening, whereas its relationship with myocardial injury requires further longitudinal investigation.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"26 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13732947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between vitamin D deficiency and liver fibrosis assessed by transient elastography in patients with metabolic dysfunction-associated steatotic liver disease. 代谢功能障碍相关脂肪变性肝病患者的瞬时弹性成像评估维生素D缺乏与肝纤维化之间的关系
IF 3.7 3区 医学
BMC Endocrine Disorders Pub Date : 2026-08-31 DOI: 10.1186/s12902-026-02527-0
Justin Jose, Salman Muhammad Soomar, Ximena Fernandez Cristobal, Zahra Khan
{"title":"Association between vitamin D deficiency and liver fibrosis assessed by transient elastography in patients with metabolic dysfunction-associated steatotic liver disease.","authors":"Justin Jose, Salman Muhammad Soomar, Ximena Fernandez Cristobal, Zahra Khan","doi":"10.1186/s12902-026-02527-0","DOIUrl":"10.1186/s12902-026-02527-0","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease is the most common chronic liver disease worldwide, affecting approximately 25-30% of adults. Liver fibrosis is the principal determinant of disease progression and mortality in MASLD. Vitamin D deficiency is highly prevalent in individuals with metabolic disorders and has been implicated in hepatic inflammation and fibrogenesis. However, the relationship between vitamin D status and liver fibrosis in MASLD remains incompletely understood, particularly in Middle Eastern populations.</p><p><strong>Methods: </strong>A retrospective cross‑sectional study was conducted at King's College Hospital London, Dubai. Adult patients with MASLD who underwent vibration‑controlled transient elastography (FibroScan<sup>®</sup>) and had serum 25‑hydroxyvitamin D [25(OH)D] measurements within 90 days were included. Liver fibrosis was assessed using FibroScan-derived liver stiffness measurement. Hepatic steatosis was evaluated using both FibroScan-derived controlled attenuation parameter measurements and abdominal ultrasound findings where available. CAP was used as the quantitative measure of steatosis, while ultrasound grades were recorded for routine clinical assessment. Associations were evaluated using chi-square and non-parametric tests as appropriate. Multivariable logistic regression was performed to assess the independent association between vitamin D deficiency and clinically significant fibrosis.</p><p><strong>Results: </strong>A total of 301 patients with MASLD were included (mean age 41.75 ± 8.90 years; 50.5% male). Vitamin D deficiency was observed in 69.76% of patients. Most patients had no to mild fibrosis (F0-F1, 80.83%), followed by significant fibrosis (F2, 14.98%), advanced fibrosis (F3, 3.48%), and cirrhosis (F4, 0.69%). Vitamin D deficiency was significantly associated with fibrosis stage (p = 0.01) and hepatic steatosis severity (p = 0.01). No significant associations were observed between vitamin D deficiency and BMI (p = 0.20), diabetes/prediabetes (p = 0.69), hypertension (p = 0.92), or dyslipidaemia (p = 0.71), while a significant association was noted with metabolic syndrome (p < 0.01). Vitamin D deficiency was not independently associated with clinically significant fibrosis (aOR 0.89, 95% CI 0.44-1.80; p = 0.754). Increasing age (aOR 1.05, 95% CI 1.01-1.09; p = 0.018) and male sex (aOR 6.23, 95% CI 2.88-13.49; p < 0.001) were independently associated with clinically significant fibrosis.</p><p><strong>Conclusion: </strong>Vitamin D deficiency is highly prevalent in this MASLD cohort and is significantly associated with greater fibrosis severity, suggesting that it may serve as a marker of disease burden. However, causality cannot be established, and prospective studies are required to determine whether vitamin D plays a causal role in disease progression.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"26 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13721371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149294623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From local control to systemic management: radiotherapy and sequential methotrexate therapy in an adult BRAF-negative hypothalamic-pituitary Langerhans cell histiocytosis - a case report with 15-month follow-up. 从局部控制到全身控制:成人braf阴性下丘脑-垂体朗格汉斯细胞组织细胞增多症的放射治疗和顺序甲氨蝶呤治疗- 15个月随访的病例报告。
IF 3.7 3区 医学
BMC Endocrine Disorders Pub Date : 2026-08-25 DOI: 10.1186/s12902-026-02509-2
Chi Feng, Zhiming Chen, Liang Chen, Jun Qin, Desheng Wei, Lei Mou
{"title":"From local control to systemic management: radiotherapy and sequential methotrexate therapy in an adult BRAF-negative hypothalamic-pituitary Langerhans cell histiocytosis - a case report with 15-month follow-up.","authors":"Chi Feng, Zhiming Chen, Liang Chen, Jun Qin, Desheng Wei, Lei Mou","doi":"10.1186/s12902-026-02509-2","DOIUrl":"10.1186/s12902-026-02509-2","url":null,"abstract":"<p><strong>Background: </strong>Langerhans cell histiocytosis (LCH) is a rare clonal neoplastic disorder characterized by the proliferation of CD1a+/Langerin+ dendritic cells. Hypothalamic-pituitary region (HPR) involvement in adults-particularly when followed by multisystem progression after local therapy-remains poorly characterized. We report a 35-year-old female with HPR-LCH who achieved durable local metabolic remission after radiotherapy but later developed systemic progression, which was successfully managed with systemic chemotherapy.</p><p><strong>Case presentation: </strong>A 35-year-old woman presented with progressive memory decline, polydipsia, polyuria, 15-kg weight gain over six months, and one year of amenorrhea. Endocrine evaluation revealed central diabetes insipidus (CDI) and hyperprolactinemia (prolactin 94.19 ng/mL). Pituitary MRI demonstrated a 2.0 × 1.4 cm enhancing hypothalamic mass with pituitary stalk thickening. A pterional craniotomy was performed for histopathological sampling, and immunohistochemistry confirmed LCH (CD1a+/Langerin+/S100+); BRAF V600E mutation was negative by quantitative PCR. The patient received involved-field intensity-modulated radiotherapy (IMRT, 22 Gy/11 fractions) targeting the HPR lesion. At 15-month follow-up, 18 F-fluorodeoxyglucose positron emission tomography-computed tomography (18 F-FDG PET-CT) demonstrated complete metabolic remission of the hypothalamic lesion, with resolution of memory and mood symptoms. However, new progressive skull bone destruction, skin ulcers, and pulmonary nodules emerged. She was subsequently treated with a full initial course of high-dose methotrexate (MTX 9 g IV weekly for 3 weeks, 12 g weekly for 2 weeks, and 16 g weekly for 2 weeks) at a Peking Union Medical College Hospital-affiliated institution, achieving significant improvement in skin ulcers, bone pain, and galactorrhea. A second consolidation course is scheduled.</p><p><strong>Conclusion: </strong>This case illustrates that involved-field IMRT can achieve durable local control of HPR-LCH even in BRAF V600E-negative cases. However, local control does not equate to systemic cure; close surveillance for extracranial progression is essential, and timely systemic chemotherapy (e.g., high-dose MTX) is critical for managing multisystem disease. Lifelong endocrine surveillance remains mandatory.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"26 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13769157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of the triglyceride-glucose index in predicting parathyroidectomy in primary hyperparathyroidism. 甘油三酯-葡萄糖指数在预测原发性甲状旁腺功能亢进患者甲状旁腺切除术中的作用。
IF 3.7 3区 医学
BMC Endocrine Disorders Pub Date : 2026-08-21 DOI: 10.1186/s12902-026-02495-5
İlkcan Çerçi Koçar, Neşe Bülbül
{"title":"Role of the triglyceride-glucose index in predicting parathyroidectomy in primary hyperparathyroidism.","authors":"İlkcan Çerçi Koçar, Neşe Bülbül","doi":"10.1186/s12902-026-02495-5","DOIUrl":"10.1186/s12902-026-02495-5","url":null,"abstract":"<p><strong>Objective: </strong>The triglyceride-glucose (TyG) index is an easily accessible novel indicator of insulin resistance. This study aimed to investigate the relationship between the TyG index and the homeostatic model assessment of insulin resistance (HOMA-IR) in patients with primary hyperparathyroidism (PHPT), compare these parameters with healthy controls, and evaluate whether the TyG index could serve as a potential new parameter in patients undergoing parathyroidectomy.</p><p><strong>Methods: </strong>We retrospectively analyzed PHPT patients diagnosed between October 2023 and May 2024 in a tertiary endocrinology clinic. TyG index and HOMA-IR were compared with age- and sex-matched healthy controls, and subgroup analyses were performed for parathyroidectomy status. Statistical tests included correlation analysis and ROC curves.</p><p><strong>Results: </strong>HOMA-IR, TyG index and HbA1c were higher in patients with hyperparathyroidism compared to the control group (p < 0.001). The area under the curve (AUC) of each curve was calculated. It was found that serum calcium (AUC: 0.910, 95% CI: 0.849-0.971), fasting serum insulin (AUC: 0.876, 95% CI: 0.799-0.953), HOMA (AUC: 0.877, 95% CI: 0.799-0.956) and TyG index (AUC: 0.859, 95% CI: 0.777-0.941) demonstrated a satisfactory diagnostic capacity, with serum calcium achieving the highest score. ROC analysis demonstrated high diagnostic performance of TyG index (AUC = 0.859, cut-off = 9.6, sensitivity 82.9%, specificity 73.0%) and HOMA-IR (AUC = 0.877, cut-off = 2.69, sensitivity 84.2%, specificity 76.3%).</p><p><strong>Conclusions: </strong>The TyG index (cut-off = 9.6) reliably identified PHPT patients requiring parathyroidectomy and may serve as a simple surrogate marker of insulin resistance.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"26 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic and hormonal correlates of leptin, uric acid and soluble neprilysin in polycystic ovary syndrome/ Polyendocrine Metabolic Ovarian Syndrome. 多囊卵巢综合征/多内分泌代谢性卵巢综合征中瘦素、尿酸和可溶性尿毒素的代谢和激素相关性
IF 3.7 3区 医学
BMC Endocrine Disorders Pub Date : 2026-08-20 DOI: 10.1186/s12902-026-02507-4
Bayram Burak Ceviz, Ozgur Baykan, Figen Efe Camili, Selim Afsar, Mine Islimye Taskin, Orkun Cetin
{"title":"Metabolic and hormonal correlates of leptin, uric acid and soluble neprilysin in polycystic ovary syndrome/ Polyendocrine Metabolic Ovarian Syndrome.","authors":"Bayram Burak Ceviz, Ozgur Baykan, Figen Efe Camili, Selim Afsar, Mine Islimye Taskin, Orkun Cetin","doi":"10.1186/s12902-026-02507-4","DOIUrl":"10.1186/s12902-026-02507-4","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Polycystic ovary syndrome (PCOS) / Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a complex endocrine and metabolic disorder in women of reproductive age. This study aimed to evaluate the relationship between serum leptin, uric acid and soluble neprilysin levels and metabolic and hormonal parameters in women with PCOS/PMOS. The evaluation of new metabolic biomarkers in conjunction with hormonal parameters may contribute to a better understanding of the metabolic aspects and pathophysiology of PCOS/PMOS.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;This case-control study was conducted on 90 women, including 60 patients diagnosed with PCOS/PMOS and 30 healthy age-matched controls. The PCOS/PMOS group was further divided into obese and non-obese subgroups according to body mass index (BMI). Demographic characteristics, Ferriman-Gallwey (FG) scores, anthropometric measurements, hormonal profiles (anti-Müllerian hormone (AMH), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone, progesterone, prolactin, estradiol), and metabolic parameters (fasting blood glucose, insulin, triglycerides, uric acid) were recorded. Venous blood samples were collected after an 8-12-hour fast during the early follicular phase of the menstrual cycle. Serum leptin and soluble neprilysin levels were measured using the ELISA method. Group comparisons, post-hoc analyses, correlation analysis, ROC analysis, age- and BMI-adjusted ANCOVA, and penalized LASSO logistic regression were performed to evaluate biomarker associations and discriminatory performance for PCOS/PMOS.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;LH, AMH, testosterone, HOMA-IR, triglycerides, uric acid, and leptin levels were significantly higher in the PCOS/PMOS group than in controls, with the most pronounced metabolic abnormalities observed in the obese PCOS/PMOS subgroup. Leptin levels were highest in obese women with PCOS/PMOS (p &lt; 0.001), whereas soluble neprilysin levels did not differ significantly among groups (p = 0.233). Correlation analyses showed that leptin was strongly associated with adiposity and insulin-resistance-related parameters, including BMI, HOMA-IR, and uric acid. ROC analysis demonstrated strong discriminatory performance for waist-to-height ratio (AUC = 0.899), testosterone (AUC = 0.895), waist-to-hip ratio (AUC = 0.891), and AMH (AUC = 0.882), while HOMA-IR, leptin, and TyG index showed acceptable discriminatory ability. After adjustment for age and BMI, only TyG index and WHR remained significantly different among groups, whereas leptin and soluble neprilysin did not. LASSO logistic regression retained AMH, testosterone, WHR, and log-transformed leptin in a parsimonious classification model, indicating that hormonal markers and central adiposity indices contributed most consistently to PCOS/PMOS classification, while the independent contribution of leptin appeared limited by its close associati","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"26 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13617861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glycated hemoglobin and bone mineral density in adults with and without type 2 diabetes: a cross-sectional DXA study from the Qassim region, Saudi Arabia. 2型糖尿病患者和非2型糖尿病患者的糖化血红蛋白和骨密度:来自沙特阿拉伯卡西姆地区的横断面DXA研究
IF 3.7 3区 医学
BMC Endocrine Disorders Pub Date : 2026-08-19 DOI: 10.1186/s12902-026-02474-w
Hajed Obaid Alharbi, Amal Hussain Mohammed, Sahar Mohammed Alatni, Layla Sharfaldeen Mohamed Ahmed, Metab Algeffari, Bassam Alkhalifah, Hamad Suliman Alsheeb, Afshan Zeeshan Wasti, Shakera Khatoon
{"title":"Glycated hemoglobin and bone mineral density in adults with and without type 2 diabetes: a cross-sectional DXA study from the Qassim region, Saudi Arabia.","authors":"Hajed Obaid Alharbi, Amal Hussain Mohammed, Sahar Mohammed Alatni, Layla Sharfaldeen Mohamed Ahmed, Metab Algeffari, Bassam Alkhalifah, Hamad Suliman Alsheeb, Afshan Zeeshan Wasti, Shakera Khatoon","doi":"10.1186/s12902-026-02474-w","DOIUrl":"10.1186/s12902-026-02474-w","url":null,"abstract":"<p><strong>Background: </strong>This comparative cross-sectional study evaluated bone mineral density (BMD) and its association with glycemic control and biochemical bone markers among adults with and without type 2 diabetes mellitus (T2DM) in the Qassim region, Saudi Arabia.</p><p><strong>Methods: </strong>A comparative cross-sectional study was conducted among 73 adults (comprising individuals with T2DM and non-diabetic controls) recruited from healthcare facilities in the Qassim region, Saudi Arabia. Clinical, demographic, and bone health data were collected using a structured questionnaire and hospital medical records. Glycated hemoglobin (HbA1c), serum calcium, alkaline phosphatase (ALP), fracture history, and bone mineral density were evaluated. BMD was measured at the lumbar spine and femoral neck using dual-energy X-ray absorptiometry (DXA) and classified according to the World Health Organization (WHO) criteria. Statistical analyses were performed using SPSS version 23.0.</p><p><strong>Results: </strong>T2DM was diagnosed in 69.9% of participants; 48.0% had osteopenia and 19.2% had osteoporosis. Chronological age was associated with progressive bone mineral density loss across successive cohorts (Pearson χ² = 11.14, p = 0.025). Among participants with T2DM, mean HbA1c increased progressively with longer diabetes duration (Spearman's rho = 0.310, p = 0.027). In an exploratory multinomial logistic regression model, higher HbA1c was associated with lower bone mineral density categories each 1% increase in HbA1c was associated with higher odds of osteopenia (adjusted odds ratio [aOR] = 2.34, 95% confidence interval [CI]: 1.12-4.88; p = 0.024) and osteoporosis (aOR = 3.89, 95% CI: 1.45-10.42; p = 0.007). Serum calcium and alkaline phosphatase (ALP) were not significantly associated with bone mineral density.</p><p><strong>Conclusions: </strong>Low bone mineral density was common in this study population. Higher HbA1c levels were associated with lower bone mineral density categories in an exploratory regression model adjusted for the variables included in the analysis. These findings support further investigation of the relationship between glycaemic control and bone health in larger prospective studies with comprehensive adjustment for clinical confounders.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"26 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13501789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148812052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of the uric acid to high-density lipoprotein cholesterol ratio with CVD mortality in Chinese hypertensive populations: a prospective cohort study. 中国高血压人群尿酸与高密度脂蛋白胆固醇比值与心血管疾病死亡率的关系:一项前瞻性队列研究
IF 3.7 3区 医学
BMC Endocrine Disorders Pub Date : 2026-08-19 DOI: 10.1186/s12902-026-02439-z
Meiqing Zeng, Chao Yu, Yumeng Shi, Peixu Zhao, Jingyang Xiao, Wei Zhou, Lingjuan Zhu, Huihui Bao, Weifang Zhang, Xiaoshu Cheng
{"title":"Association of the uric acid to high-density lipoprotein cholesterol ratio with CVD mortality in Chinese hypertensive populations: a prospective cohort study.","authors":"Meiqing Zeng, Chao Yu, Yumeng Shi, Peixu Zhao, Jingyang Xiao, Wei Zhou, Lingjuan Zhu, Huihui Bao, Weifang Zhang, Xiaoshu Cheng","doi":"10.1186/s12902-026-02439-z","DOIUrl":"https://doi.org/10.1186/s12902-026-02439-z","url":null,"abstract":"<p><strong>Background: </strong>Uric acid to high-density lipoprotein cholesterol ratio (UHR) is a novel index of metabolism and inflammation proposed by recent studies. The predictive value of UHR has been validated in non‑alcoholic fatty liver disease. However, the association of UHR is undetermined in patients with hypertension. The aim of this study was to investigate the association of UHR with all-cause mortality and CVD mortality in patients with hypertension.</p><p><strong>Methods: </strong>This study was conducted in a real-world setting using data from a large-scale, population-based registry in China. The outcome was all-cause and CVD mortality. Cox proportional hazards models were used to investigate the associations between UHR and mortality from all-causes and cardiovascular. Penalized spline method, the Kaplan-Meier method, and subgroup analyses were also used.</p><p><strong>Results: </strong>13719 patients with hypertension were included in the study. During a median follow-up of 4.3 years,772 all-cause mortality occurred, with 378 CVD mortality. The mean baseline UHR was 12.53 ± 5.34. Overall, higher UHR was conspicuously associated with an elevated risk of CVD mortality and all cause mortality. Accordingly, compared with participants in quartiles 1, a conspicuous higher risk of all-cause mortality (HR = 1.52, 95% CI: 1.15, 2.01) and CVD mortality (HR = 2.54, 95% CI: 1.63,3.95) were found in quartile 4. No significant interactions were found in any of the subgroups.</p><p><strong>Conclusions: </strong>Among Chinese adults with hypertension, an elevated UHR predicted increased risk of all-cause and CVD mortality in patients.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"26 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13761033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书